In solely metastatic NSCLC patients (n = 21), combined RT to oligoprogressive sites along with PD-1/PD-L1 blockade or other immune therapies resulted in excellent local control, median time to systemic progression of 2.3 months (95% confidence interval (CI) 1.0–4.5), and median OS of 7.2 months (95% CI 4.2–11.1) [118]. Here, PDCD1 is linked to non-small cell lung carcinoma.